Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 6, 2017, Pages 1068-1075

  Zhang, Jifeng ^a   Niimi, Manabu ^b   Yang, Dongshan ^a   Liang, Jingyan ^a   Xu, Jie ^a   Kimura, Tokuhide ^b   Mathew, Anna V ^a   Guo, Yanhong ^a   Fan, Yanbo ^a   Zhu, Tianqing ^a   Song, Jun ^a   Ackermann, Rose ^c   Koike, Yui ^a   Schwendeman, Anna ^c   Lai, Liangxue ^d   Pennathur, Subramaniam ^a   Garcia Barrio, Minerva ^a   Fan, Jianglin ^b   Eugene Chen, Y ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

^d GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

apolipoprotein; atherosclerosis; cholesterol reduction; cholesteryl ester transfer protein genetics; high density lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; CHOLESTEROL INTAKE; SELE PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DNA END JOINING REPAIR; EMBRYO; ENDOTHELIUM CELL; FEMALE; GENE EDITING; GENE EXPRESSION; GENE TARGETING; GENOTYPE; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT MODEL; STOP CODON; ANIMAL; AORTIC DISEASES; ATHEROSCLEROSIS; BLOOD; CELL LINE; CHOLESTEROL INTAKE; CORONARY ARTERY DISEASE; DEFICIENCY; DISEASE MODEL; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; PATHOLOGY; RABBITS AND HARES; TIME FACTOR; TRANSGENIC ANIMAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; AORTIC DISEASES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; E-SELECTIN; FEMALE; GENE EDITING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; LIPID METABOLISM, INBORN ERRORS; MACROPHAGES; MALE; MICE; RABBITS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85018844030     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.309114     Document Type: Article

References (29)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 62 707 714
2. Degoma EM, Rader DJ, Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 2011 8 266 277. doi: 10.1038/nrcardio.2010.200.
3. Tall AR, Plasma cholesteryl ester transfer protein. J Lipid Res 1993 34 1255 1274
4. Barter PJ, Nicholls SJ, Kastelein JJ, Rye KA, Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP inhibition as a strategy to reduce cardiovascular risk: The Pro Case. Circulation 2015 132 423 432. doi: 10.1161/CIRCULATIONAHA.114.014025.
5. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989 342 448 451. doi: 10.1038/342448a0.
6. Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S, Hui DY, Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest 1990 86 688 695. doi: 10.1172/JCI114764.
7. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y, A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998 27 5 pt 1 659 667. doi: 10.1006/pmed.1998.0340.
8. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR, Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990 323 1234 1238. doi: 10.1056/NEJM199011013231803.
9. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR, Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996 97 2917 2923. doi: 10.1172/JCI118751.
10. Barter P, CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000 20 2029 2031
11. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD, Marsh HC, Ryan US, Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000 20 2106 2112
12. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A, Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998 273 5033 5036
13. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000 406 203 207. doi: 10.1038/35018119.
14. Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ, Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in new zealand white rabbits. J L ipid R es 2007 48 1263 1272
15. Miyosawa K, Watanabe Y, Murakami K, Murakami T, Shibata H, Iwashita M, Yamazaki H, Yamazaki K, Ohgiya T, Shibuya K, Mizuno K, Tanabe S, Singh SA, Aikawa M, New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. Am J Physiol Endocrinol Metab 2015 309 E177 E190. doi: 10.1152/ajpendo.00528.2014.
16. Aghebati T, Badiee A, Mohammadpour AH, Afshar M, Jaafari MR, Abnous K, Issazadeh S, Hashemzadeh S, Zareh M, Hashemizadeh H, Nazemi S, Anti-atherosclerosis effect of different doses of CETP vaccine in rabbit model of atherosclerosis. Biomed Pharmacother 2016 81 468 473. doi: 10.1016/j.biopha.2016.04.035.
17. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H, Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002 103 587 594. doi: 10.1042/.
18. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW, Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993 364 73 75. doi: 10.1038/364073a0.
19. Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628.
20. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 356 1304 1316. doi: 10.1056/NEJMoa070635.
21. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797.
22. McLain JH, Alsterda AJ, Arora RR, Cholesteryl ester transfer protein inhibitors: Trials and tribulations. J C ardiovasc P harmacol T her 2016 pii: 1074248416662349
23. Fan J, Kitajima S, Watanabe T, Xu J, Zhang J, Liu E, Chen YE, Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine. Pharmacol Ther 2015 146 104 119. doi: 10.1016/j.pharmthera.2014.09.009.
24. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, Hocking TD, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Amacher SL, Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 2008 26 702 708. doi: 10.1038/nbt1409.
25. Kovanen PT, Brown MS, Basu SK, Bilheimer DW, Goldstein JL, Saturation and suppression of hepatic lipoprotein receptors: A mechanism for the hypercholesterolemia of cholesterol-fed rabbits. Proc Natl Acad Sci USA 1981 78 1396 1400
26. Xu G, Salen G, Shefer S, Ness GC, Nguyen LB, Parker TS, Chen TS, Zhao Z, Donnelly TM, Tint GS, Unexpected inhibition of cholesterol 7 alpha-hydroxylase by cholesterol in New Zealand white and Watanabe heritable hyperlipidemic rabbits. J Clin Invest 1995 95 1497 1504. doi: 10.1172/JCI117821.
27. Haraki T, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H, Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis 1997 132 229 236
28. Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y, Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2015 385 2153 2161. doi: 10.1016/S0140-6736(14)62115-2.
29. Zhang Z, Yamashita S, Hirano K, Nakagawa-Toyama Y, Matsuyama A, Nishida M, Sakai N, Fukasawa M, Arai H, Miyagawa J, Matsuzawa Y, Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis 2001 159 67 75